Maygarden S J, Novotny D B, Moul J W, Bae V L, Ware J L
Department of Pathology, University of North Carolina at Chapel Hill.
Mod Pathol. 1994 Dec;7(9):930-6.
Differential reactivity for cathepsin D (cath-D) and epidermal growth factor receptor (EGFR) was compared in 102 archival cases of human primary prostatic carcinoma and nine prostate carcinoma metastases by immunohistochemical techniques using commercially available antibodies (Ciba-Corning, Triton Diagnostics Division, Alameda, CA). Western immunoblotting confirmed that the anti-cath-D and anti-EGFR antibodies recognized the appropriate-sized proteins in extracts of human prostatic carcinoma cell lines. For immunohistochemical analysis, the primary prostate carcinomas ranged from Gleason's combined scores of 2 to 9. High-grade prostatic intraepithelial neoplasia was coexistent in 79 of the cases. Immunohistochemical staining was scored by summing the intensity of staining (0 to 3+) weighted by the percentage of tumor staining at each intensity (H score, theoretical range 0 to 300). Heterogenous moderate to strong reactivity with anti-cath-D was detected in 96 of 102 cases of primary prostate carcinoma (94%), with a mean H score of 176.5. EGFR reactivity was much less common and less strong, with 41 of 102 primary prostate carcinomas staining (40%) at a mean H score intensity of 29.2. The immunohistochemical (H) scores of cath-D and EGFR reactivity both significantly correlated with the Gleason's combined score of the tumors. There was no significant correlation between the cath-D and EGFR scores. Ninety-nine percent of the examples of prostatic intraepithelial neoplasia were reactive with anti-cath-D, with no clear correlation between the intensity of staining of prostatic intraepithelial neoplasia and the adjacent carcinoma.(ABSTRACT TRUNCATED AT 250 WORDS)
采用市售抗体(加利福尼亚州阿拉米达市汽巴-康宁公司,Triton诊断部),通过免疫组化技术,在102例人原发性前列腺癌存档病例和9例前列腺癌转移病例中比较了组织蛋白酶D(cath-D)和表皮生长因子受体(EGFR)的差异反应性。蛋白质免疫印迹法证实,抗cath-D和抗EGFR抗体在人前列腺癌细胞系提取物中识别出大小合适的蛋白质。免疫组化分析中,原发性前列腺癌的Gleason综合评分范围为2至9分。79例病例中并存高级别前列腺上皮内瘤变。免疫组化染色评分通过将染色强度(0至3+)乘以各强度下肿瘤染色百分比(H评分,理论范围0至300)求和得出。102例原发性前列腺癌病例中有96例(94%)检测到与抗cath-D呈异质性中度至强反应性,平均H评分为176.5。EGFR反应性则少见且较弱,102例原发性前列腺癌中有41例(40%)染色,平均H评分强度为29.2。cath-D和EGFR反应性的免疫组化(H)评分均与肿瘤的Gleason综合评分显著相关。cath-D和EGFR评分之间无显著相关性。99%的前列腺上皮内瘤变样本与抗cath-D反应,前列腺上皮内瘤变的染色强度与相邻癌之间无明显相关性。(摘要截断于250字)